Bioregulators & Organ Support
Epithalon (Epitalon)
← Back to Library
Protocol not independently verified FDA safety flag Longevity Circadian
Educational reference only. Read the full disclaimer.
The protocols below are not automatically an FDA-approved or clinically verified regimen unless
explicitly marked as label-verified or human-trial protocol above.
Overview
Route(s): Subcutaneous
Typical vial sizes: 10, 40, 50 mg
Dosing window: Pre-Bed
Receptor / target: TERT
Properties: Not stated
Pre-mixed: No
Protocol examples
Standard Protocol
| Timeframe | Dose | Notes |
|---|---|---|
| Days 1-20 | 5 mg 1x daily | Complete 20 consecutive days. Administer at bedtime to align with natural pineal melatonin synthesis window. Repeat twice yearly (every 6 months). |
Protocol example from the source dataset; verify against the evidence status and listed sources.
Alternative Titration 1: Anecdotal Pulse Protocol (not an Epithalamin study protocol)
| Timeframe | Dose | Notes |
|---|---|---|
| Day 1 | 10mg 1x daily at bedtime | Site-only pulse entry. Do not read Russian/Ukrainian Epithalamin literature as proof that synthetic Epithalon should be used at 10 mg. Treat this as high-uncertainty and not label dosing. |
| Day 5 | 10mg 1x daily at bedtime | Site-only pulse entry. Do not read Russian/Ukrainian Epithalamin literature as proof that synthetic Epithalon should be used at 10 mg. Treat this as high-uncertainty and not label dosing. |
| Day 9 | 10mg 1x daily at bedtime | Site-only pulse entry. Do not read Russian/Ukrainian Epithalamin literature as proof that synthetic Epithalon should be used at 10 mg. Treat this as high-uncertainty and not label dosing. |
| Day 13 | 10mg 1x daily at bedtime | Site-only pulse entry. Do not read Russian/Ukrainian Epithalamin literature as proof that synthetic Epithalon should be used at 10 mg. Treat this as high-uncertainty and not label dosing. |
| Day 17 | 10mg 1x daily at bedtime | Site-only pulse entry. Do not read Russian/Ukrainian Epithalamin literature as proof that synthetic Epithalon should be used at 10 mg. Treat this as high-uncertainty and not label dosing. |
| Day 21 | 10mg 1x daily at bedtime | Site-only pulse entry. Do not read Russian/Ukrainian Epithalamin literature as proof that synthetic Epithalon should be used at 10 mg. Treat this as high-uncertainty and not label dosing. |
| Day 25 | 10mg 1x daily at bedtime | Site-only pulse entry. Do not read Russian/Ukrainian Epithalamin literature as proof that synthetic Epithalon should be used at 10 mg. Treat this as high-uncertainty and not label dosing. |
Site-provided alternative protocol; the 10 mg Epithalon pulse is not established by Epithalamin studies.
Alternative Titration 2: High-Uncertainty Intensive Protocol
| Timeframe | Dose | Notes |
|---|---|---|
| Days 1-10 | 10mg 1x daily at bedtime | High-uncertainty site-only entry. The 10 mg/day figure is not established by the classic Epithalamin literature and should not be presented as proven human Epithalon dosing. |
Site-provided alternative protocol; high-dose Epithalon use is not established by Epithalamin studies.
Alternative Titration 3: Longevity Foundation Stack (inspired by pineal/thymic bioregulator literature, not a direct replication)
| Timeframe | Dose | Notes |
|---|---|---|
| Days 1-10 | 5mg Epithalon SC at bedtime + 10mg Thymalin SC at any time + DSIP 100-500mcg SC at bedtime (30 min before Epithalon) | Three-compound concurrent protocol inspired by the pineal/thymic bioregulator literature, but not a direct replication because the classic studies used Epithalamin rather than synthetic Epithalon. DSIP administered first at bedtime to initiate delta wave sleep induction; Epithalon administered 30 minutes later to align with the deepening slow-wave sleep window. Thymalin can be administered at any time of day. Separate injection sites for each compound. Baseline immune panel (CD3/CD4/CD8/NK) and telomere length assessment before initiating. |
| Days 11-20 | 5mg Epithalon SC at bedtime + DSIP 100-500mcg SC at bedtime | Thymalin standard course completes at Day 10. Continue Epithalon full 20-day standard course with DSIP support throughout. The sequential completion of Thymalin before Epithalon should not be described as a direct Khavinson-study replication. |
Site-provided alternative protocol; not a direct replication of Epithalamin studies.
Alternative Titration 4: Senolytic Synergy Protocol: Epithalon + FOXO4-DRI (Goal: combine telomerase-mediated prevention of future senescent cell accumulation (Epithalon) with active clearance of existing senescent cells (FOXO4-DRI); most mechanistically complete cellular aging intervention in the database)
| Timeframe | Dose | Notes |
|---|---|---|
| Days 1-3 | 1.5 mg/kg FOXO4-DRI SC on Days 1, 2, and 3 | FOXO4-DRI senolytic pulse first. Run FOXO4-DRI standard 3-day clearing course before Epithalon initiation. Rationale: clear existing senescent cell burden before activating telomerase to protect new cell generations: clearing the old first, then protecting the new. |
| Days 4-23 | 5mg Epithalon SC 1x daily at bedtime | Begin Epithalon standard 20-day course immediately following FOXO4-DRI clearing course. The cleared cellular environment allows Epithalon's TERT activation to act on the surviving non-senescent cell population without competition from the high oxidative and inflammatory burden of the pre-existing senescent cell mass. |
Alternative example from the source dataset; not an approved-label regimen unless marked above.
Alternative Titration 5: Circadian Restoration and Melatonin Axis Protocol (Goal: prioritize pineal melatonin rhythm normalization and circadian amplitude restoration; indicated for subjects with severe circadian dysfunction, poor sleep architecture, shift work history, or measured low nocturnal melatonin output; complements Endoluten oral cytomedin)
| Timeframe | Dose | Notes |
|---|---|---|
| Days 1-5 | 2.5mg Epithalon SC at bedtime | Half-dose titration entry for subjects whose primary goal is circadian restoration rather than maximum TERT activation. Lower dose reduces vivid dream intensity in first days while melatonin rhythm re-establishes. Baseline salivary DLMO melatonin test before initiating. |
| Days 6-20 | 5mg Epithalon SC at bedtime | Full standard dose for remainder of course. Combine with Endoluten 2 capsules before dinner on Days 1-30 for comprehensive pineal cytomedin (Endoluten) + defined synthetic peptide (Epithalon) coverage of the pineal aging axis simultaneously. Salivary melatonin DLMO retest at Day 30. |
Alternative example from the source dataset; not an approved-label regimen unless marked above.
Protocol logic check
Protocol context: Bioregulator protocols are often cycle-based because the claim is organ-system signaling rather than acute symptom control. The logic should be organ-specific labs, medical context, and humility about older or vendor-derived evidence. Entry context: target (TERT); route Subcutaneous; timing Pre-Bed. Unapproved or source-dataset dosing tables are hypotheses, not recommendations. FDA/safety flags lower confidence and raise the evidence bar for any claimed benefit. Do not treat Epithalamin studies as direct Epithalon dosing proof. Epithalamin is a pineal extract/bioregulator; Epithalon/Epitalon is the synthetic AEDG tetrapeptide. The popular 10 mg/day claim is not established by the classic Russian/Ukrainian Epithalamin literature, so the protocol notes flag high-dose entries as site-only and high-uncertainty.
Independent evidence
Independent safety notes: FDA lists epitalon among withdrawn nominated bulk substances with insufficient route-specific safety information. Major dosing caveat: much of the Russian/Ukrainian human pineal-peptide literature used Epithalamin, a pineal extract/bioregulator, not synthetic Epithalon/Epitalon. Do not convert those papers into a 10 mg/day Epithalon rule.
Regulatory status: unapproved or compounded peptide with FDA safety risk flag
Storage
No approved-label storage guidance was identified for this entry. Use conservative sterile handling and see the general storage guidance in the FAQ.
Contraindications & cautions
Evidence varies by item. Some points come from labels, published literature, or regulatory context; others are mechanism-based cautions from the source dataset. Use the sources below to verify details.
- Active malignancy with rapidly proliferating tumor cells: telomerase activation is the primary mechanism of Epithalon; malignant cells already exploit telomerase (TERT) re-expression as a core immortalization strategy; exogenous TERT stimulation in the context of active cancer could theoretically accelerate tumor cell telomere maintenance and proliferative capacity; use in subjects with known active malignancy requires oncological evaluation.
- Known TERT-expressing malignancy (most carcinomas, lymphomas, certain sarcomas): same mechanism as above; the subset of cancers most reliant on TERT for immortality represent the highest-risk context for Epithalon use.
- Known hypersensitivity to Epithalon, epithalamin-derived peptides, or formulation excipients.
- Pregnancy: the epigenetic and telomeric effects of TERT activation during fetal development are not characterized; pineal gland modulation during organogenesis is not established as safe.
- Breastfeeding: no safety data.
- Concurrent use of telomerase inhibitor investigational agents (in oncology trials): Epithalon's TERT activation directly opposes the mechanism of experimental telomerase inhibitor anticancer therapies.
- Pre-existing conditions of telomere lengthening dysregulation (dyskeratosis congenita variants with TERT gain-of-function): in the rare context of existing TERT hyperactivation pathology, additional TERT stimulation is inadvisable.
Possible side effects
Evidence varies by item. Some points come from labels, published literature, or regulatory context; others are mechanism-based cautions from the source dataset. Use the sources below to verify details.
- Vivid dreams and altered dream intensity: the most consistently reported subjective adverse effect; Epithalon's restoration of pineal melatonin secretion and improvement in slow-wave sleep architecture produces dramatically more vivid, narrative, and emotionally rich dreaming; typically experienced as a positive effect but can be disorienting in subjects with prior dream suppression (common with sleep deprivation or alcohol use).
- Altered sleep architecture: the first 1-5 days of a new Epithalon cycle may produce transient sleep architecture changes as the pineal melatonin rhythm is re-establishing; subjects may experience unusually deep sleep, difficulty waking at normal times, or altered REM/NREM proportions.
- Mild transient fatigue: reported in a minority of subjects in the first days of a cycle; likely related to the acute melatonin rhythm normalization.
- Injection site mild reaction: standard subcutaneous peptide injection response; minimal.
- Transient mood changes: a small subset of subjects reports mild mood elevation or transient emotional sensitivity during the first week; related to melatonin normalization and its effects on serotonin synthesis pathways (melatonin is downstream of serotonin in pinealocyte biosynthesis).
- No endocrine disruption beyond pineal normalization: Epithalon does not affect the HPA axis, sex hormones, thyroid, or growth hormone axis directly; all secondary hormonal effects are downstream of the pineal melatonin restoration.
- No documented toxicity at standard doses in the 40+ year Russian clinical use history: the safety profile of Epithalon across decades of Russian and Ukrainian clinical application is exceptionally clean; no serious adverse events have been documented in the published Khavinson literature at standard protocol doses.
- Theoretical cancer promotion risk (not documented in clinical data): the TERT activation mechanism raises the theoretical concern above; however, in the 40+ year human use history including elderly subjects (who have the highest background cancer incidence), no increase in cancer rates has been documented: and the published data shows reduced cancer incidence; this remains a mechanistic theoretical concern not supported by the available observational data.
Compatibility
The relationships below come from the source site's internal engine and were not verified independently. Treat them as a starting point for a conversation with a clinician. They carry no safety guarantee.
Reported synergistic:
Reported contraindicated combinations:
None listed.
Sources
- https://the source dataset.com/peptide-codex.php
- https://www.fda.gov/drugs/guidance-compliance-regulatory-information/human-drug-compounding
- https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks?pg=3
- https://pubmed.ncbi.nlm.nih.gov/14523363/
- https://pubmed.ncbi.nlm.nih.gov/40141333/
- https://pubmed.ncbi.nlm.nih.gov/11335874/
- PubMed search: Epithalon (Epitalon)